Treating gastrointestinal malignancy with proton therapy
The improved dosimetry with proton therapy enables greater sparing of normal tissues...
The improved dosimetry with proton therapy enables greater sparing of normal tissues...
Published in the Green Journal, this study by the group of New York Proton Center compared the dosimetric quality between an PBS Bragg peak FLASH and...
Proton particles do not deposit exit dose, which allows proton therapy to spare normal tissues distal to the tumor target. This is particularly useful for...
During ISOP 2022, Williams Graeme presented "Managing In-Field 2nd Primary Cancer". Watch the webinar above.
What is on the horizon with IBA Dosimetry and Proton Therapy? Watch this webinar to learn about QA and how it will be integrated with our future developments.
A review article by the Upenn group summarized the preclinical and clinical evidence for the FLASH effect and discussed the potential clinical significance for...
This study evaluated 68 patients with atypical teratoid/rhabdoid tumors (ATRT) treated with surgery (65% initial gross total resection or GTR), chemotherapy (60...
This study evaluated dosimetric and cognitive data from 75 patients with medulloblastoma treated with proton (n=36) and photon (n=39). Significant dose...